Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Adv Ther ; 17(6): 263-71, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11317829

RESUMO

Respiratory tract infections (RTIs), the most common indication for outpatient antimicrobial therapy, impose a heavy medical and societal burden and present a difficult therapeutic challenge in the face of increasing pathogen resistance worldwide. Gatifloxacin is a new broad-spectrum fluoroquinolone with excellent activity against prevalent respiratory bacteria, including penicillin-resistant Streptococcus pneumoniae and atypical pathogens. A multicenter, open-label, noncomparative surveillance study carried out in Mexico evaluated the safety and efficacy of oral gatifloxacin 400 mg once daily in 17,923 adult outpatients with community-acquired pneumonia (CAP) (n = 3322), acute exacerbations of chronic bronchitis (AECB) (n = 5885), and acute bacterial sinusitis (n = 8716). Voluntary, unpaid physician participation contributed to an unbiased study design. Physician-assessed global rate of cure or improvement was 96.3%; efficacy was 95.8% in CAP, 96.1% in AECB, and 96.4% in sinusitis. The incidences of relapse (1.5%) and therapeutic failure (0.7%) were low. The most commonly reported adverse events, nausea (2.76%), headache (2.20%), and dizziness (1.33%), were generally mild and self-limited. Oral gatifloxacin 400 mg once daily is effective and safe for patients with CAP, AECB, and acute sinusitis.


Assuntos
Assistência Ambulatorial/métodos , Anti-Infecciosos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Bronquite/tratamento farmacológico , Infecções Comunitárias Adquiridas/tratamento farmacológico , Fluoroquinolonas , Pneumonia/tratamento farmacológico , Infecções Respiratórias/tratamento farmacológico , Segurança , Sinusite/tratamento farmacológico , Doença Aguda , Administração Oral , Adulto , Infecções Bacterianas/microbiologia , Bronquite/microbiologia , Infecções Comunitárias Adquiridas/microbiologia , Tontura/induzido quimicamente , Resistência Microbiana a Medicamentos , Feminino , Gatifloxacina , Cefaleia/induzido quimicamente , Humanos , Masculino , México , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Pneumonia/microbiologia , Estudos Prospectivos , Recidiva , Infecções Respiratórias/microbiologia , Sinusite/microbiologia , Resultado do Tratamento
2.
Rev Invest Clin ; 44(2): 169-86, 1992.
Artigo em Espanhol | MEDLINE | ID: mdl-1439306

RESUMO

In this paper a family evaluation instrument called systemic-psychodynamic family evaluation model is described. Also, the second stage of the validation study of this instrument is presented (which deals with the inter-observers variation). Twenty families were studied. They were assessed always by the same interviewers designated as experts. They are all family therapy specialists and their assessment was used as the evaluation reference standard or "gold standard". The observers were psychiatrists without previous training in family therapy. For the purpose of the interview, both experts and observers were blind to the medical diagnosis of the patients. During the first stage of the validation study the observers did not have a reference guide which resulted in a low concordance rating. For the second stage, a 177 item guide was used and a considerable increase in the concordance rating was observed. Validation studies like the one used here are of considerable value to increase the reliability and further utilisation of evaluation instruments of this type.


Assuntos
Terapia Familiar , Família/psicologia , Modelos Psicológicos , Testes Psicológicos , Estudos de Avaliação como Assunto , Humanos , Individuação , Entrevista Psicológica , Transtornos Mentais/psicologia , Variações Dependentes do Observador , Reprodutibilidade dos Testes , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA